Tuesday, 22 July 2014

Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market: 2018

Pills
Methicillin-resistant staphylococcus aureus (MRSA) infections are caused due to Staphylococcus aureus bacterium which infects different parts of the body. These infections are difficult to treat due to high degree of resistance of these pathogens to the most commonly used antibiotics such as methicillin, amoxicillin, penicillin and oxacillin. The bacterium infects different parts of the body namely, skin, surgical wounds, blood streams, lungs, IV or other sites where the tubes such as catheters enter the body or the urinary tract and cause infection which can be life threatening.

MRSA infection is known to spread by casual contact or through contaminated objects called community associated MRSA (CA MRSA). It may also be acquired in hospitals or health care settings - healthcare associated MRSA (HA MRSA) which is the most common form of MRSA infection. Community associated methicillin resistant S. aureus (CA-MRSA) infections are different from healthcare associated methicillin resistant S. aureus (HA-MRSA) considering their epidemiology and the characteristics of the strains which causes the infection. Overuse of antibiotics and use of potent drugs for less serious infections may also cause development of MRSA. The symptoms of infection depend on the site of infection and it can be diagnosed by laboratory testing.

One of the major drivers contributing to the market growth for MRSA drugs is increase in the prevalence of MRSA infections. In addition, growth in the government and non-government awareness programs has also become a key factor in improving the market growth. However, overcoming the tendency of pathogen for developing resistance to multi-drugs and increase in competition between the generic market players could impose a challenge to the market growth.

MRSA can be usually treated by antibiotics such as bactrim and vancomycin though the pathogen has started developing resistance for these drugs too owing to its constant adapting power to newly developed antibiotics. Other options for the treatment of MRSA infection are generics such as clindamycin and minocycline, and prime brand-names such as Tygacil, Cubicin, Zyvox, and Synercid. Some of these antibiotics are only available intravenously. The most effective way of controlling the spread of MRSA is practicing basic hygiene such as use of disposable gloves, washing hands before making direct contact with patients as well as proper wound care.

Geographically, North America leads this market and is followed by Europe. However, increase in the development of healthcare infrastructure in emerging economies forecasts growth in demand for MRSA drugs in Asia-Pacific and other parts of the world. Some of the major players in this market include Takeda Pharmaceutical Company Limited, Merck & Co., Inc, AstraZeneca PLC, GlaxoSmithKline PLC, Pfizer, Inc., Cubist Pharmaceuticals, Inc., ViroPharma, Inc., Forest Laboratories, Inc., and Theravance, Inc.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
  • North America
  • Asia Pacific
  • Europe
  • Rest of the World
This report provides comprehensive analysis of
  • Market growth drivers
  • Factors limiting market growth
  • Current market trends
  • Market structure
  • Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

About us
Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.

TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.

Contact Us
Sheela AK
Corporate Office:
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States.
Tel: +1-518-618-1030
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

No comments:

Post a Comment